The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.
Holbrook Edwin Kohrt
No relevant relationships to disclose
Roch Houot
No relevant relationships to disclose
Kipp Weiskopf
No relevant relationships to disclose
Matthew Goldstein
No relevant relationships to disclose
Peder Lund
No relevant relationships to disclose
Ruth R Lira
No relevant relationships to disclose
Emily Troutner
No relevant relationships to disclose
Lori Richards
No relevant relationships to disclose
Amanda Rajapaksa
No relevant relationships to disclose
Anton Ostashko
No relevant relationships to disclose
Wen-Kai Weng
No relevant relationships to disclose
Lieping Chen
No relevant relationships to disclose
Debra Czerwinski
No relevant relationships to disclose
A. Dimitrios Colevas
No relevant relationships to disclose
John Sunwoo
No relevant relationships to disclose
Ronald Levy
No relevant relationships to disclose